Turn this role into an interview — a resume and cover letter built around what this employer wants.
FDA ORISE program at White Oak, Maryland offers a research fellowship in the Office of Tissues and Advanced Therapies (OTAT), CBER. Fellows work under PhD scientists to develop in vitro methods to replace animal testing for antivenom potency and study long-term stability of non-US antivenoms.
The program emphasizes creativity and hypothesis-driven experiments. Participants are trained, not employees of FDA, with stipends commensurate with education level; onboarding requires background checks
U.S. Food and Drug Administration (FDA)
FDA-CBER-2026-0083
10/9/2026 3:00:00 PM Eastern Time Zone
A research opportunity is currently available at the Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) in White Oak, Maryland.
The ORISE Research Participation Program at the U.S. Food and Drug Administration is an educational and training program designed to provide college students, recent graduates, and university faculty opportunities to connect with the unique resources of the FDA. The Center for Biologics Evaluation and Research (CBER) is one Center within the Food and Drug Administration, an Agency within the United States Government's Department of Health and Human Services. CBER's mission is to protect and enhance the public health through the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies.
You will join the primary research program to research and gain experience on replacement of animal testing, to determine the potency of licensed US snake antivenoms. Secondarily, the laboratory is evaluating the long-term stability of non-US antivenoms. Non-US antivenoms (“exotic” antivenoms) are used for treatment of non-US venomous snakes (cobras, kraits, mambas, etc.). Such species are held in zoos, research facilities, venom producing facilities, and by private individuals. Exotic antivenoms are also acquired by US military for treatment of personnel positioned in other nations. Since no US licensed company makes exotic antivenoms, they are imported from other countries where the snakes are indigenous, and such antivenoms are manufactured. For the primary project, the lab is developing in vitro methods to tests (in vitro) the activity of US antivenoms, to replace the currently used mouse lethality assay. You will be trained by PhD scientists in the laboratory. None of the research involves venomous snakes. You will be allowed to make creative modifications to the methods, based on research publications, and will be encouraged to design experiments and test hypotheses.
The mentor for this opportunity is Dorothy Scott (Dorothy.Scott@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.
Fall 2026. Start date is flexible and will depend on a variety of factors.
The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.
The appointment is full time.
The participant will receive a monthly stipend commensurate with educational level and experience.
This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on‑boarded at FDA. OPM can complete a background investigation only for individuals, including non‑US Citizens, who have resided in the US for a total of three of the past five years.
If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.
The qualified candidate should have received a bachelor's, master's or doctoral degree in one of the relevant fields (e.g. Biology, Cellular Immunology, Bioengineering, Immunology, Herpetology, Hematology, Biochemistry), or be currently pursuing one of the degrees. Degree must have been received within the past five years, or be currently pursuing to receive by 9/30/2026.
Ashley
I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)
I have read the FDA Ethics Requirements.